Global expansion Polpharma is expanding its footprint with offices in India and Southern Asia, enhancing global collaboration and API supply chain resilience. This presents opportunities to offer contract manufacturing, API partnerships, and regional distribution arrangements to support their growing international operations.

M&A momentum Recent acquisition of Biofarm SA signals capacity for expanded product lines and regional market access. Sales teams can target integration support, transfer of manufacturing agreements, and bridging supply for generics across Central and Eastern Europe and neighboring markets.

RNA platform Launch of RNA-based medicines platform in Starogard Gdański indicates focus on advanced therapies. Opportunities exist to provide formulation development, analytical testing, and scalable manufacturing services for RNA therapeutics and related bioprocessing capabilities.

Leadership transition New President appointed, signaling strategic direction and potential initiatives in global growth and modernization. Engage to align offerings with upcoming corporate priorities, including international partnerships, digitalization, and broadened product portfolios.

Industry position Strong presence as a leading generic producer in Central and Eastern Europe and Kazakhstan with substantial revenue and a large workforce. Prospect for value-based contracts, long-term supply agreements, and enhanced service levels with contract development and manufacturing organizations (CDMOs) to support scale and regional demand.